经皮冠状动脉介入治疗继以单药治疗代替双重抗血小板治疗治疗急性冠状动脉综合征:NEO-MINDSET 试验 (NEOMINDSET)
经皮冠状动脉介入治疗继以单药治疗代替双重抗血小板治疗治疗急性冠状动脉综合征:NEO-MINDSET 试验 巴西统一卫生系统中针对急性冠状动脉综合征患者的减药研究
3 期、随机、多中心、平行组研究,对终点进行盲法评估和意向治疗分析。
该研究的一般目的是评估在接受经皮冠状动脉介入治疗的急性冠脉综合征患者中,与常规双重抗血小板治疗相比,血小板 P2Y12 受体抑制剂作为单一疗法引起的缺血事件的非劣效性假设和出血事件的优越性假设巴西统一卫生系统的背景。
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
研究类型
研究类型
注册 (实际的)
注册
阶段
阶段
- 第三阶段
联系人和位置
学习联系方式
学习联系方式
- 姓名:Pedro A Lemos, MD
- 电话号码:+55 (11) 98317-5000
- 邮箱:pedro.lemos@einstein.br
研究联系人备份
- 姓名:Marcelo Franken, MD
- 电话号码:+55 (11) 99277-3509
- 邮箱:marcelo.franken@einstein.br
学习地点
-
-
-
Rio De Janeiro、巴西
- Instituto Estadual de Cardiologia Aloysio de Castro
-
São Paulo、巴西
- Hospital São Paulo - UNIFESP
-
São Paulo、巴西、05652- 900
- Hospital israelita Albert Einstein
-
-
BA
-
Salvador、BA、巴西
- Hospital Ana Nery
-
-
CE
-
Fortaleza、CE、巴西
- Hospital de Messejana Dr. Carlos Alberto Studart Gomes
-
-
DF
-
Brasília、DF、巴西
- Hospital de Base de Brasília
-
Brasília、DF、巴西
- Instituto Aramari Apo
-
-
ES
-
Linhares、ES、巴西
- Instituto Cardiovascular de Linhares
-
Vila Velha、ES、巴西
- Hospital Evangélico de Vila Velha
-
Vitória、ES、巴西
- Hospital Santa Casa de Misericórdia de Vitória
-
-
GO
-
Goiânia、GO、巴西
- Universidade Federal de Goias
-
Goiânia、GO、巴西
- Hospital Municipal Aparecida de Goiânia
-
-
MG
-
Belo Horizonte、MG、巴西
- Hospital Felicio Rocho
-
Belo Horizonte、MG、巴西
- Hospital Madre Teresa
-
Belo Horizonte、MG、巴西
- Hospital Universitário Ciências Médicas de Belo Horizonte
-
Poços De Caldas、MG、巴西
- Hospital Santa Lucía
-
Uberaba、MG、巴西
- Hospital de Clínicas da Universidade Federal do Triângulo Mineiro
-
-
MS
-
Campo Grande、MS、巴西
- Hospital Universitário Maria Aparecida Pedrossian
-
-
Mato Grosso do Sul
-
Campo Grande、Mato Grosso do Sul、巴西
- CASSEMS
-
-
Minas Gerais
-
Juiz De Fora、Minas Gerais、巴西
- Eurolatino
-
Passos、Minas Gerais、巴西
- Santa Casa da Misericórdia de Passos
-
-
Minas gerais
-
Belo Horizonte、Minas gerais、巴西
- Instituto Orizonti
-
-
PE
-
Recife、PE、巴西
- Hospital Real Português
-
-
Paraná
-
Curitiba、Paraná、巴西
- Pontifícia Universidade Católica do Paraná
-
-
Pernambuco
-
Recife、Pernambuco、巴西
- Instituto de Medicina Integral Professor Fernando Figueira - IMIP
-
-
RJ
-
Rio De Janeiro、RJ、巴西
- Hospital São Lucas
-
Rio De Janeiro、RJ、巴西
- HUPE - Hospital Universitário Pedro Ernesto
-
Rio De Janeiro、RJ、巴西
- Instituto Nacional de Cardiologia - INC
-
-
RS
-
Porto Alegre、RS、巴西
- Hospital de Clinicas de Porto Alegre
-
Porto Alegre、RS、巴西
- Hospital Sao Lucas da PUCRS
-
Porto Alegre、RS、巴西
- Instituto de Cardiologia do RS - Fundação Universitária de Cardiologi
-
-
Rio Grande do Norte
-
Natal、Rio Grande do Norte、巴西
- Instituto Atena de Pesquisa
-
-
SC
-
Florianópolis、SC、巴西
- Hospital Baía Sul
-
Florianópolis、SC、巴西
- Hospital Instituto de Cardiologia de SC
-
-
SE
-
Aracaju、SE、巴西
- Centro de Pesquisa Clínica do Coração
-
-
SP
-
Bragança Paulista、SP、巴西
- Hospital Universitário São Francisco na Providência de Deus
-
Campinas、SP、巴西
- Instituição, Hospital e Maternidade Celso Pierro
-
Campinas、SP、巴西
- UNICAMP
-
Marilia、SP、巴西
- Irmandade da Santa Casa de Misericórdia de Marília
-
Osasco、SP、巴西
- Hospital Municipal Antonio Giglio
-
Santos、SP、巴西
- Santa Casa da Misericórdia de Santos
-
São Paulo、SP、巴西
- Instituto de Assistência Médica ao Servidor Público Estadual
-
São Paulo、SP、巴西
- Hospital 9 De Julho
-
São Paulo、SP、巴西
- Hospital Dante Pazzanese
-
São Paulo、SP、巴西
- Instituto do Coração - InCor
-
São Paulo、SP、巴西
- Real e Benemerita Associacao Portuguesa de Beneficencia
-
-
São Paulo
-
Botucatu、São Paulo、巴西
- UPECLIN
-
Campinas、São Paulo、巴西
- Instituto de Pesquisa Clínica de Campinas
-
Presidente Prudente、São Paulo、巴西
- Hospital Regional de Presidente Prudente
-
São José Do Rio Preto、São Paulo、巴西
- Hospital de Base
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
描述
纳入标准:
受试者必须满足以下所有标准:
- 年龄 >=18 岁;
- 临床表现与入院前 24 小时内发作的急性冠脉综合征相符;
- 使用新一代药物洗脱支架对所有目标病变(罪魁祸首和非罪魁祸首)进行成功的经皮冠状动脉介入治疗;
- 随机化住院时间 < 96 小时;
- 受试者将被告知研究的性质,并且必须同意遵守并使用当地伦理委员会事先批准的表格以书面形式给予知情同意。
排除标准:
符合以下任何标准的受试者将被排除在外:
- 入院时的急性冠脉综合征以保守方式或不成功的经皮介入治疗或手术治疗;
- 存在可能需要在未来 12 个月内进行进一步治疗的残留病灶;
- 纤维蛋白溶解治疗 < 随机分组前 24 小时;
- 需要华法林或新型抗凝剂口服抗凝;
- 慢性出血素质;
- 活动性或近期大出血(住院);
- 既往颅内出血;
- 缺血性脑血管意外<30天;
- 存在脑动静脉畸形;
- 非动脉粥样硬化血栓病因的指标事件(即支架内血栓形成、冠状动脉栓塞、自发性冠状动脉夹层、供需失衡导致的心肌缺血);
- 未来 12 个月内可能或预定的心脏或非心脏手术;
- 血小板计数 < 100,000 个细胞/mm3 或 > 700,000 个细胞/mm3;
- 总白细胞计数 < 3,000 个细胞/mm3;
- 疑似或有记录的活动性肝病(包括乙型或丙型肝炎的实验室证据);
- 心脏移植接受者;
- 已知对乙酰水杨酸、氯吡格雷、噻氯匹定、替格瑞洛、普拉格雷、肝素或莫司家族的抗增殖剂过敏或不耐受;
- 受试者预期寿命低于 1 年;
- 研究者认为可能影响受试者理想参与研究的任何重大医疗状况;
- 在过去 12 个月内参加过其他研究,除非可以预期对受试者有直接益处。
- 根据研究者判断,不可能接受双重抗血小板治疗 12 个月。
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
手臂数量
武器和干预
参与者组/臂参与者组/臂 |
干预/治疗干预/治疗 |
|---|---|
|
无干预:双重抗血小板疗法
随机分解为双重抗血小板治疗对照组的受试者将用乙酰水杨酸与ticagrelor或prasugrel结合使用12个月。 乙酰水杨酸(每天100 mg/天) + ticagrelor(每天两次90 mg)或乙酰酸酸(100 mg/天) + prasugrel(每天5mg或10 mg) |
|
|
实验性的:抗血小板单一疗法
随机分配给单一治疗组的所有受试者将在随机分组后立即停用乙酰水杨酸。 随机分配给单一疗法组的受试者将单独使用ticagrelor或prasugrel治疗12个月。 单独使用Ticagrelor(每天两次90毫克)或单独使用Prasugrel(每天5或10毫克) |
随机分配给单一治疗组的所有受试者将在随机分组后立即停用乙酰水杨酸。 随机分配给单一治疗组的受试者将仅用ticagrelor或prasugrel治疗,直到研究结束为止,第12个月。
其他名称:
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
全因死亡率,中风,心肌梗塞或紧急目标血运重建的综合终点。
大体时间:12个月
|
共同疗效终点(非效率假设)
|
12个月
|
|
出血学术研究联盟(BARC)2、3或5级出血事件
大体时间:12个月
|
共有安全终点(优越性假设)
|
12个月
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
猝死
大体时间:30天
|
猝死
|
30天
|
|
心肌梗塞
大体时间:12个月
|
心肌梗塞
|
12个月
|
|
支架内血栓
大体时间:12个月
|
支架内血栓
|
12个月
|
|
BARC 1-5 型出血
大体时间:12个月
|
BARC 1-5 型出血
|
12个月
|
|
性价比
大体时间:12个月
|
性价比
|
12个月
|
|
中风
大体时间:12个月
|
中风
|
12个月
|
|
全因死亡,心血管死亡和非心血管死亡
大体时间:12个月
|
全因死亡,心血管死亡和非心血管死亡
|
12个月
|
|
外侵袭性冠状动脉治疗
大体时间:12个月
|
外侵袭性冠状动脉治疗
|
12个月
|
|
净不良临床事件(发生全因死亡,心肌梗死,中风,紧急目标血运重建,BARC 2、3或5出血)
大体时间:12个月
|
净不良临床事件(发生全因死亡,心肌梗死,中风,紧急目标血运重建,BARC 2、3或5出血)
|
12个月
|
合作者和调查者
调查人员
调查人员
- 首席研究员:Pedro A Lemos, MD、Hospital israelita Albert Einstein
出版物和有用的链接
一般刊物
- Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449. No abstract available.
- Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419. No abstract available.
- Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW; Academic Research Consortium. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Circulation. 2018 Jun 12;137(24):2635-2650. doi: 10.1161/CIRCULATIONAHA.117.029289.
- Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA, Wallentin L; PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011 Aug 2;124(5):544-54. doi: 10.1161/CIRCULATIONAHA.111.047498. Epub 2011 Jun 27.
- Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009 Feb 28;373(9665):723-31. doi: 10.1016/S0140-6736(09)60441-4.
- Feres F, Costa RA, Siqueira D, Costa JR Jr, Chamie D, Staico R, Chaves AJ, Abizaid A, Marin-Neto JA, Rassi A Jr, Botelho R, Alves CMR, Saad JA, Mangione JA, Lemos PA, Quadros AS, Queiroga MAC, Cantarelli MJC, Figueira HR. DIRETRIZ DA SOCIEDADE BRASILEIRA DE CARDIOLOGIA E DA SOCIEDADE BRASILEIRA DE HEMODINAMICA E CARDIOLOGIA INTERVENCIONISTA SOBRE INTERVENCAO CORONARIA PERCUTANEA. Arq Bras Cardiol. 2017 Jun;109(1 Suppl 1):1-81. doi: 10.5935/abc.20170111. No abstract available. Portuguese.
- Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, Topol EJ. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol. 2005 May 15;95(10):1218-22. doi: 10.1016/j.amjcard.2005.01.049.
- Xian Y, Wang TY, McCoy LA, Effron MB, Henry TD, Bach RG, Zettler ME, Baker BA, Fonarow GC, Peterson ED. Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. Circulation. 2015 Jul 21;132(3):174-81. doi: 10.1161/CIRCULATIONAHA.114.014992. Epub 2015 May 20.
- Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, Gaglione A, Goldberg SL, Tobis JM. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995 Mar 15;91(6):1676-88. doi: 10.1161/01.cir.91.6.1676.
- Vranckx P, Valgimigli M, Juni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Mollmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S; GLOBAL LEADERS Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018 Sep 15;392(10151):940-949. doi: 10.1016/S0140-6736(18)31858-0. Epub 2018 Aug 27.
- Kogame N, Modolo R, Tomaniak M, Cavalcante R, de Martino F, Tinoco J, Ribeiro EE, Mehran R, Campos CM, Onuma Y, Lemos PA, Serruys PW; Collaborators. Prasugrel monotherapy after PCI with the SYNERGY stent in patients with chronic stable angina or stabilised acute coronary syndromes: rationale and design of the ASET pilot study. EuroIntervention. 2019 Aug 9;15(6):e547-e550. doi: 10.4244/EIJ-D-19-00131. No abstract available.
- Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, Cooper DJ, Marasco S, McNeil J, Bussieres JS, Wallace S; ATACAS Investigators of the ANZCA Clinical Trials Network. Stopping vs. Continuing Aspirin before Coronary Artery Surgery. N Engl J Med. 2016 Feb 25;374(8):728-37. doi: 10.1056/NEJMoa1507688.
- Valgimigli M, Frigoli E, Leonardi S, Rothenbuhler M, Gagnor A, Calabro P, Garducci S, Rubartelli P, Briguori C, Ando G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van 't Hof A, Boccuzzi G, Omerovic E, Sabate M, Heg D, Juni P, Vranckx P; MATRIX Investigators. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med. 2015 Sep 10;373(11):997-1009. doi: 10.1056/NEJMoa1507854. Epub 2015 Sep 1.
- Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019 Aug 14;40(31):2632-2653. doi: 10.1093/eurheartj/ehz372.
- Lansky AJ, Messe SR, Brickman AM, Dwyer M, Bart van der Worp H, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Scala Moy C, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. Eur Heart J. 2018 May 14;39(19):1687-1697. doi: 10.1093/eurheartj/ehx037.
- Frigoli E, Smits P, Vranckx P, Ozaki Y, Tijssen J, Juni P, Morice MC, Onuma Y, Windecker S, Frenk A, Spaulding C, Chevalier B, Barbato E, Tonino P, Hildick-Smith D, Roffi M, Kornowski R, Schultz C, Lesiak M, Iniguez A, Colombo A, Alasnag M, Mullasari A, James S, Stankovic G, Ong PJL, Rodriguez AE, Mahfoud F, Bartunek J, Moschovitis A, Laanmets P, Leonardi S, Heg D, Sunnaker M, Valgimigli M. Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. Am Heart J. 2019 Mar;209:97-105. doi: 10.1016/j.ahj.2018.10.009. Epub 2018 Nov 22.
- Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators; Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045-57. doi: 10.1056/NEJMoa0904327. Epub 2009 Aug 30.
- Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD; Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction; Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiade M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S; ESC Committee for Practice Guidelines (CPG). Third universal definition of myocardial infarction. Eur Heart J. 2012 Oct;33(20):2551-67. doi: 10.1093/eurheartj/ehs184. Epub 2012 Aug 24. No abstract available.
- Guimaraes PO, Franken M, Tavares CAM, Silveira FS, Antunes MO, Bergo RR, Joaquim RM, Hirai JCS, Andrade PB, Pitta FG, Mariani J Jr, Nascimento BR, de Paula JET, Silveira MS, Costa TAO, Dall'Orto FTC, Serpa RG, Sampaio FBA, Ohe LN, Mangione FM, Furtado RHM, Sarmento-Leite R, Monfardini F, Assis SRL, Nicolau JC, Sposito AC, Lopes RD, Onuma Y, Valgimigli M, Angiolillo DJ, Serruys PW, Berwanger O, Bacal F, Lemos PA. P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients with acute coronary syndromes undergoing coronary stenting: rationale and design of the NEOMINDSET Trial. EuroIntervention. 2023 Jul 17;19(4):e323-e329. doi: 10.4244/EIJ-D-23-00125.
- Valgimigli M, Garcia-Garcia HM, Vrijens B, Vranckx P, McFadden EP, Costa F, Pieper K, Vock DM, Zhang M, Van Es GA, Tricoci P, Baber U, Steg G, Montalescot G, Angiolillo DJ, Serruys PW, Farb A, Windecker S, Kastrati A, Colombo A, Feres F, Juni P, Stone GW, Bhatt DL, Mehran R, Tijssen JGP. Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). Eur Heart J. 2019 Jul 1;40(25):2070-2085. doi: 10.1093/eurheartj/ehy377.
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (实际的)
初级完成
研究完成 (实际的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他研究编号
其他研究编号
- 3992
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.